stockrowVeracyte, Inc.
VCYT Healthcare Diagnostics & Research
Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024.
- Revenue
- +15.1%
- EPS
- +62.5%
- Free cash flow
- −9.63%
Quarter to September 2026, against a year earlier
Follow VCYT
Alert me
Veracyte, Inc. (VCYT) Shares outstanding
Veracyte, Inc.'s shares outstanding at the end of fiscal 2025 was $80.6M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $82.8M. Over the past ten years it has ranged from $26.0M (fiscal 2015) to $80.6M (fiscal 2025) — the current reading is the highest in ten years. Veracyte, Inc. ranks 20th of 49 Diagnostics & Research companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $80.6M | 3.08% |
| FY2024 | $78.2M | 7.60% |
| FY2023 | $72.6M | 1.53% |
| FY2022 | $71.5M | 5.39% |
| FY2021 | $67.9M | 27.52% |
| FY2020 | $53.2M | 15.39% |
| FY2019 | $46.1M | 24.63% |
| FY2018 | $37.0M | 9.12% |
| FY2017 | $33.9M | 17.68% |
| FY2016 | $28.8M | 10.91% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $82.8M | 0.88% |
| Jun 2026 | $82.1M | 0.92% |
| Mar 2026 | $81.3M | 0.92% |
| Dec 2025 | $80.6M | 1.11% |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| SHC Sotera Health Company compare | $289.2M |
| ADPT Adaptive Biotechnologies Corporation compare | $186.9M |
| NEO NeoGenomics, Inc. compare | $128.6M |
| VCYT Veracyte, Inc. | $82.8M |
| RDNT RadNet, Inc. compare | $78.7M |
| CDNA CareDx, Inc. compare | $55.0M |
| BLLN BillionToOne, Inc. compare | $53.7M |
| GRAL GRAIL, Inc. compare | $46.8M |
| WGS GeneDx Holdings Corp. compare | $29.7M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on VCYT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement